NEW YORK, NY, and CAMBRIDGE, MA NOVEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial.
How Tokenization can Transform Pharma Licensing and Royalty Financing The pharmaceutical and biotech industries face a critical financing paradox: groundbreaking medical innovations require massive capital investment, yet traditional funding mechanisms create significant barriers to accessing the capital needed to bring life-saving treatments to market.
Royalty financing and synthetic royalties are reshaping biotech and pharma funding in Europe. As venture funding tightens—Q2 2025 saw biotech venture capital drop to $4.8B, falling to pre-2018 levels—European companies are increasingly adopting alternative funding models. Notably, over 20% of global synthetic royalty and drug development deals now involve European players, a major leap in just two years.
